Faculty

Institution

Unit

Venue

Joseph Drabick

Professor of Medicine

Pennsylvania State University

Affiliations

Penn State College of Medicine

Department of Medicine

Division of Hematology and Oncology

Joseph Drabick is currently serving as a Medicine Professor of Medicine at Pennsylvania State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Joseph Drabick

Pennsylvania State University

Professor of Medicine

You can click a keyword to filter the displayed items

oncology cancer research cancer treatment cancer care medicine radiation oncology pharmacology clinical research medicinal research urology cancer immunotherapy tumor biology melanoma cancer biology cancer management cellular therapy surgical oncology immunotherapy leukemia anti-cancer agents therapeutic targets tumor targeting pharmacotherapy cancer genomics oncogenes molecular cancer skin cancer radiation therapy cancer genetics clinical radiation oncology hematology novel therapies genitourinary cancers hematological malignancies metastatic melanoma gynecologic oncology cancer imaging cancer cells genome biology breast oncology therapeutic efficacy lymphoid neoplasia advanced melanoma overall survival cancer discovery malignant disease enzyme inhibition genomic medicine treatment development concurrent durvalumab adjuvant durvalumab urothelial cancer molecular diagnostics histopathology receptor tyrosine kinases immune checkpoint inhibitors disease progression cancer growth drug targeting acute myeloid leukemia concurrent ipilimumab shorter overall survival tumor suppressors renal pathophysiology clinical pharmacology medical genetics genome instability malignant blood disorders health care costs systematic review neoadjuvant chemotherapy phase ii trial phase ii study localized urothelial cancer prognostic value neoadjuvant combination immunotherapy cancer institute brain tumor research pathology clinical translation

Notable Scholarly Works

Notable Federal Grants

Collaborators

Angelica Gigas Nakai (Korean Dang-Gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy – Active Phytochemicals and in Vivo Molecular Targets. Pharmaceutical Research (2025)

Junxuan LüCheng JiangJoseph J. DrabickMonika JoshiStuthi Perimbeti

pharmacognosyhealth promotionactive phytochemicalsnatural productsbioactive compoundspharmacologytherapeutic targetsphytochemicalsvivo molecular targetskorean dang-guinatural product researchherbal medicinebotanyphytotherapy researchphytochemical analysispharmaceutical researchphytochemistrydisease therapyphytopharmacologyalcoholic extractsmedicineantioxidantsbiomolecular engineering

Abstract Ct145: The Final Results of a Phase I Study Using Velcade (Bortezomib), Cladribine, and Rituximab (Vcr) in Treating Elderly Patient With Mantle Cell Lymphoma. Cancer Research (2024)

Jeffrey J. PuKristin BergerDavid ClaxtonJoseph DrabickThomas LoughranElliot Epner

elderly patientradiation oncologycancer carecell therapymantle cell lymphomamedicinal researchsurgical oncologycancer researchmedicinecancer managementclinical researchcancer treatmentlymphoid neoplasiahealth sciencesoncologycancer biology

A Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab in Treating Patients Over 50 Years Old With Mantle Cell Lymphoma. Frontiers in Oncology (2024)

Jeffrey J. PuKristin N. BergerChunlei ZhengNhan DoDavid F. ClaxtonW. Christopher EhmannJoseph J. DrabickHaiquan LiThomas P. LoughranElliot M. Epner

mantle cell lymphomamedicinecancer treatmentlymphoid neoplasiaoncology

A Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (Vcr) in Treating Elderly Patients With Mantle Cell Lymphoma. Research Square (2024)

Jeffrey J. PuKristin N. BergerChunlei ZhengNhan DoMary T. BrophyDavid F. ClaxtonW Christopher EhmannJoseph J. DrabickHaiquan LiThomas P. LoughranElliot M. Epner

mantle cell lymphomahematologydermatologyelderly patientspharmacologymedicineclinical researchcancer careoncology

EDITORIAL: Checkpoint Inhibition in Hematologic Malignancies. Frontiers in Oncology (2024)

Jeffrey J. PuJoseph J. DrabickSusan E. Prockop

hematologic malignanciescheckpoint inhibitionhematological malignanciescancer researchmedicinecancer treatmentoncology

Impact of Bone Metastasis in Stage IV Non–Small Cell Lung Cancer Treated With Durvalumab and Tremelimumab With or Without Chemotherapy: A Retrospective Analysis of the Cctg Br.34 Trial. JCO oncology advances. (2024)

Charyguly AnnageldiyevPierre-Olivier GaudreauKim LeitzelSuhail M. AliKeyue DingNatasha B. LeighlFrancisco Emilio Vera BadilloPenelope Ann BradburyGlenwood D. GossLois E. ShepherdLuis CostaLarry J. SuvaBrett G.M. HughesMartin R. StocklerJoseph J. DrabickPatrick C. MaMonika JoshiPrashanth MokuHyma V. PolimeraPatricia LouisPriya RamachandrulaAllan Lipton

gynecologic oncologysurgical oncologythoracic oncologybone researchspinal oncologylung cancerradiologycancer researchjama oncologycancer treatmentradiation oncologygastrointestinal oncologyurologycancer managementclinical trialsbone metastasismetastasiscohort studiesretrospective analysisoncology

Tumor Heterogeneity Shapes Survival Dynamics in Drug-Treated Cells, Revealing Size-Drifting Subpopulations. ACS Pharmacology & Translational Science (2024)

Venugopal VangalaYu-Chi ChenSaketh S. DinavahiKrishne GowdaNazir A. LoneMeenhard HerlynJoseph DrabickKlaus HelmJiyue ZhuRogerio I. NevesArun K. SharmaArthur BergMarco ArchettiShantu AminTodd D. SchellGavin P. Robertson

drug-treated cellstumor biologytranslational researchmedicinal researchsize-drifting subpopulationssurvival dynamicstreatment developmentclinical researchmedicinepharmacologysystems biologytumor heterogeneityoncologycancer biologytumor microenvironment

A Phase 2 Study of Alrizomadlin, a Novel Mdm2/P53 Inhibitor, in Combination With Pembrolizumab for Treatment of Patients With Malignant Peripheral Nerve Sheath Tumor (Mpnst).. Journal of Clinical Oncology (2023)

Neeta SomaiahBrian Andrew Van TineBartosz ChmielowskiJoseph J. DrabickSant P. ChawlaMeredith McKeanAlexander I. SpiraKenneth John O'ByrneSteven A. ForestoSujana MovvaAeRang KimBrian GastmanJoseph Gerald PresseyBen PaudyalAsit DeRobert E. WinklerMingyu LiMohammad AhmadDajun YangYifan Zhai

radiation oncologymedical mycologycancer managementanti-cancer agentsdrug targetingcancer immunotherapycancer treatmentmedicinal researchcancer researchmedicinepharmacologytherapeutic targetsclinical researchpharmacotherapyclinical pharmacologyenzyme inhibitioncancer careoncology

A Phase 2 Study of Alrizomadlin (Apg-115) in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Cutaneous Melanoma That Has Failed Immuno-Oncologic (Io) Drugs.. Journal of Clinical Oncology (2023)

Montaser F. ShaheenJennifer Margaret SegarBartosz ChmielowskiJoseph J. DrabickMeredith McKeanJames A. ReevesChristos Stelios KarapetisMarlana M. OrloffAnthony W. TolcherJ. Thaddeus Thaddeus BeckBrian GastmanAsit DeBen PaudyalRobert E WinklerMingyu LiMohammad AhmadDajun YangYifan Zhai

metastasistumor targetingmetastatic cutaneous melanomaimmunologymedicinal researchskin cancerdermatologymelanomadrug resistancecancer researchtreatment developmentpharmacologyclinical researchpharmacotherapyimmune checkpoint inhibitorsoncology

Concurrent Durvalumab and Radiation Therapy (Duart) Followed by Adjuvant Durvalumab in Patients With Localized Urothelial Cancer of Bladder: Results From Phase II Study, Btcrc-Gu15-023. Journal for ImmunoTherapy of Cancer (2023)

Monika JoshiLeonard TuanquinJunjia ZhuVonn WalterTodd SchellMatthew KaagDeepak KilariJiangang LiaoSheldon L HolderHamid EmamekhooAlexander SankinSuzzane MerrillHong ZhengJoshua WarrickRalph HaukeBenjamin GartrelMark SteinJoseph DrabickDavid J DegraffYousef Zakharia

radiation therapyradiation oncologycancer immunotherapyimmunotherapyconcurrent durvalumablocalized urothelial cancermedicineadjuvant durvalumaburologycancer treatmentcancer managementoncologyphase ii study

1
2
3
4
5
15
10 / page

Joseph Drabick

Professor of Medicine

Pennsylvania State University

Affiliations

Penn State College of Medicine

Department of Medicine

Division of Hematology and Oncology

Joseph Drabick is currently serving as a Medicine Professor of Medicine at Pennsylvania State University.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Joseph Drabick

Pennsylvania State University

Professor of Medicine

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Angelica Gigas Nakai (Korean Dang-Gui) Root Alcoholic Extracts in Health Promotion and Disease Therapy – Active Phytochemicals and in Vivo Molecular Targets. Pharmaceutical Research (2025)

Junxuan LüCheng JiangJoseph J. DrabickMonika JoshiStuthi Perimbeti

Abstract Ct145: The Final Results of a Phase I Study Using Velcade (Bortezomib), Cladribine, and Rituximab (Vcr) in Treating Elderly Patient With Mantle Cell Lymphoma. Cancer Research (2024)

Jeffrey J. PuKristin BergerDavid ClaxtonJoseph DrabickThomas LoughranElliot Epner

A Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab in Treating Patients Over 50 Years Old With Mantle Cell Lymphoma. Frontiers in Oncology (2024)

Jeffrey J. PuKristin N. BergerChunlei ZhengNhan DoDavid F. ClaxtonW. Christopher EhmannJoseph J. DrabickHaiquan LiThomas P. LoughranElliot M. Epner

mantle cell lymphomamedicinecancer treatmentlymphoid neoplasiaoncology

A Phase I Study Using Bortezomib (Velcade), Cladribine, and Rituximab (Vcr) in Treating Elderly Patients With Mantle Cell Lymphoma. Research Square (2024)

Jeffrey J. PuKristin N. BergerChunlei ZhengNhan DoMary T. BrophyDavid F. ClaxtonW Christopher EhmannJoseph J. DrabickHaiquan LiThomas P. LoughranElliot M. Epner

mantle cell lymphomahematologydermatologyelderly patientspharmacologymedicineclinical researchcancer careoncology

EDITORIAL: Checkpoint Inhibition in Hematologic Malignancies. Frontiers in Oncology (2024)

Jeffrey J. PuJoseph J. DrabickSusan E. Prockop

hematologic malignanciescheckpoint inhibitionhematological malignanciescancer researchmedicinecancer treatmentoncology

Tumor Heterogeneity Shapes Survival Dynamics in Drug-Treated Cells, Revealing Size-Drifting Subpopulations. ACS Pharmacology & Translational Science (2024)

1
2
3
4
5
15
10 / page

Similar Faculty Members

Afshin Dowlati

Institution

Case Western Reserve University

cancer letter

bronchial neoplasm

Peter J. O'Dwyer

Institution

University of Pennsylvania

oncology

pharmacology

Elisabeth Heath

Institution

Wayne State University

translational research

prostate cancer research

Scott Joseph Antonia

Institution

Duke University

oncology

cancer research

Heather Wakelee

Institution

Stanford University

radiation oncology

mesothelioma

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine

Barbara Burtness

Institution

Yale University

receptor tyrosine kinase

kras inhibition

Walter M. Stadler

Institution

University of Chicago

oncology

urology

Margaret K. Callahan

Institution

University of Connecticut

molecular cancer

checkpoint blockade

Patricia LoRusso

Institution

Yale University

drug trial

cancer treatment

Similar Faculty Members

Afshin Dowlati

Institution

Case Western Reserve University

cancer letter

bronchial neoplasm

Peter J. O'Dwyer

Institution

University of Pennsylvania

oncology

pharmacology

Elisabeth Heath

Institution

Wayne State University

translational research

prostate cancer research

Scott Joseph Antonia

Institution

Duke University

oncology

cancer research

Heather Wakelee

Institution

Stanford University

radiation oncology

mesothelioma

Seongho Kim

Institution

Wayne State University

data analysis

personalized medicine

Barbara Burtness

Institution

Yale University

receptor tyrosine kinase

kras inhibition

Walter M. Stadler

Institution

University of Chicago

oncology

urology

Margaret K. Callahan

Institution

University of Connecticut

molecular cancer

checkpoint blockade

Patricia LoRusso

Institution

Yale University

drug trial

cancer treatment